SYNOPSIS
Introduction
Warfarin is one of the commonest causes of death related to prescription drugs, but when used appropriately it is one of the most beneficial drugs. As the population ages and more trials show its benefits, more and older patients will be started on warfarin. Its pharmacology is complicated and many factors need to be considered in the optimal management of each patient.
Risks and benefits of warfarin
There are many indications for warfarin therapy ( Table 1) . The decision to start warfarin depends on an assessment of each patient's balance between the harmful effects and the benefits of anticoagulation.
The major adverse effect of warfarin is an increased bleeding tendency and many factors can increase the risk (Table 2) . 1 A patient's risk of bleeding is greatest in the first few months after starting warfarin. Bleeding complications occur in 3-10% of patients on warfarin per year, but most bleeds are minor. Although the bleeding risk increases as the INR (International Normalised Ratio) increases, 50% of bleeding episodes occur while the INR is less than 4.0.
Age is one of the strongest risk factors for bleeding. In one study, the annual risk of major bleeding was 2.9% for patients older than 70 years, while no major bleeds occurred in patients under Table 1 The common indications for warfarin therapy
Supported with good evidence
• prosthetic valve replacement
• deep vein thrombosis within the last three months
• pulmonary embolism within the last six months
• recurrent deep vein thrombosis or pulmonary embolism
• atrial fibrillation associated with valvular heart disease • atrial fibrillation without structural heart disease in patients >50 years old
• embolic stroke
Supported but limited evidence
• congestive heart failure or dilated cardiomyopathy
Little or no supporting evidence
• non-embolic cerebrovascular disease
• peripheral vascular disease Table 2 Risk factors for major bleeding in patients on warfarin
Marked increase in risk
• age >70 years old
• bleeding disorder
• gastrointestinal haemorrhage within the last 18 months
• previous stroke
• liver disease
• history of falls
Moderate increase in risk
• age 60-70 years
• chronic renal failure
• change in interacting medications (see Table 4) • change in, or poor, nutrition
• first three months of warfarin therapy
• large fluctuations in INR 50 years old. 2 Bleeding in this report was called 'major' if it was fatal, was intracranial, retroperitoneal or involved a joint, required surgery, led to a haemoglobin fall of 2 g/dL or more, and/or required the transfusion of two or more units of blood.
Warfarin in pregnancy is teratogenic and causes peripartum bleeding in mother and child, so it is generally contraindicated in pregnancy. There may be a place for mid-trimester warfarin in pregnant women with prosthetic heart valves, but this choice should be made only after a full discussion of the implications with the patient. Unfractionated heparin and low molecular weight heparin are alternatives that do not cross the placenta.
Patient education
Patients who have a poor understanding of the indications and potential adverse effects are more likely to be non-compliant than those who receive education about warfarin. 3 Patients should be encouraged to:
• report any signs of bleeding while on warfarin
• have more frequent measurements of their INR when starting or stopping other medications, either prescribed or complementary
• keep a written record of INR results and warfarin dosage
• remain with one or other of the currently available brands of warfarin (Coumadin or Marevan), as these have not been formally shown to be bioequivalent and are therefore not interchangeable.
Booklets aimed at patient education are available from all pharmacies. These are a useful supplement to the doctor's advice.
Women of childbearing age should be informed of the potential dangers of warfarin in pregnancy. Pre-conception counselling is needed for women on long-term treatment.
Trials of patient-based self-monitoring and dose-adjustment of warfarin therapy are under way, but currently this cannot be recommended.
Starting warfarin therapy
Patients with acute thromboembolic events, such as deep vein thrombosis, pulmonary embolism or embolic stroke, should be given heparin or low molecular weight heparin when starting warfarin. The heparin or low molecular weight heparin can be ceased after a minimum period of five days of combined therapy with warfarin and after the INR has been in the therapeutic range for 48 hours. Patients at less immediate risk, such as patients in stable atrial fibrillation without embolic events, may be safely started on warfarin without concurrent heparin.
Several trials have shown that low dose induction regimens cause fewer episodes of over-anticoagulation, with only minimal delay in the time to achieve the target INR. One protocol, validated specifically in elderly patients, is given in Table 3 . 4 Loading regimens of 5 mg warfarin per day in all patients have also been reported. 5 Previously, a modified Fennerty's protocol, using loading doses of 10 mg, 10 mg and 5 mg on the first three days, has been the most commonly used nomogram for starting warfarin. However, this protocol can lead to significant over-anticoagulation, particularly in the elderly. 4 With all induction protocols, a baseline INR is measured before starting warfarin, and the INR is measured each day until doses are stabilised. Many hospitals have anticoagulation clinics for managing patients on warfarin, although most patients can be safely managed in the community. However, clinical trials suggest that patients managed at an anticoagulant clinic spend more time with a therapeutic INR and have a lower rate of major haemorrhage, compared to 'best usual care'. 7 Patients most likely to benefit from anticoagulation clinics include those with comorbidities, those with unstable INRs and those very sensitive to warfarin (requiring daily doses of 1 mg or less). 
Maintaining warfarin therapy
The target INR varies for different clinical situations. 6 For patients with mechanical prosthetic heart valves, the target INR is usually 2.5-3.5. For almost all other conditions, including deep vein thrombosis and pulmonary embolism, atrial fibrillation and tissue valve replacements, the target INR is usually 2.0-3.0. Patients with recurrent thromboembolic events while anticoagulated, and patients with cancer or antiphospholipid syndrome may benefit from a higher INR, but this approach should be undertaken with specialist advice.
Interactions with warfarin
Warfarin is particularly prone to interactions with other drugs, herbal medicines 8 and dietary factors (Table 4) . Some interactions involve the cytochrome P450 system in the liver. Many interactions are unpredictable, so the INR should be tested more frequently after starting a new medication and similarly when stopping a medication or changing the dose. It takes about five days for enzyme induction to take place, so that an INR measured about one week after a change in medication should reflect any interaction. In one study, recent antibiotic use was the second greatest risk factor (after age) for over-anticoagulation. 9 Alcohol in small to moderate amounts probably has little effect on warfarin metabolism. In heavy drinkers, however, factors such as increased falls, alcohol-induced gastritis, poor diet and poor compliance potentiate the risk of bleeding.
The amount of vitamin K in the diet partly determines the sensitivity to warfarin. A diet high in vitamin K reduces the response. This is important to consider in situations when diet changes, such as during illness, travel, fad diets, hospitalisation and postoperatively. Foods high in vitamin K include green tea, turnips, avocados, brussel sprouts, broccoli and green leafy vegetables (e.g. lettuce, cabbage). It takes a very large daily intake of 'greens' to influence the INR. In any case, a consistently sustained diet will minimise this potential source of fluctuating results. 
Management of over-anticoagulation
Over-anticoagulation increases the risk of haemorrhage. The first step in managing this problem is to identify the cause. Common causes include starting or stopping an interacting medication, deteriorating liver function, and patient error (such as taking the wrong dose or confusing different strength tablets). Many of these causes are preventable.
The approach to a raised INR should be individualised, paying attention to the indication for the warfarin, the patient's risk of bleeding and whether it is safe to continue therapy at all. Some patients need to be admitted to hospital, while others just need to miss a dose of warfarin.
Guidelines for managing over-anticoagulation (Table 5 ) are based on the recently published recommendations from the Australasian Society of Thrombosis and Haemostasis. 10 The half-life of vitamin K is shorter than that of warfarin, so the INR may rebound 24-48 hours after giving vitamin K. The intravenous preparation of vitamin K can be administered orally or subcutaneously with equal efficacy, and these routes are usually safer and more convenient in patients who are not actively bleeding. E-mail: alexander.gallus@flinders.edu.au
